PHIO — Phio Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Phio Pharmaceuticals Corp expected to post a loss of 31 cents a share - Earnings Preview
Brief: Phio Pharmaceuticals Presents Study Outline Of Its First Clinical Trial With Ph-762 For Advanced Melanoma At The 2022 Asco Annual Meeting
Brief: Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity Of HER2-CAR-T Cells At Asgct 2022
Phio Pharmaceuticals Corp reports results for the quarter ended in March - Earnings Summary
Brief: Phio Pharmaceuticals Reports Q1 2022 Results And Provides Business Update
Phio Pharmaceuticals Corp expected to post a loss of 30 cents a share - Earnings Preview
Brief: Phio Pharmaceuticals - Announced Departure Of Gerrit Dispersyn From His Role As President And CEO
Brief: Phio Pharmaceuticals Corp - Effective As Of April 27, Increased Size Of Board To Eight Members
Brief: Phio Pharmaceuticals Announces The Appointment Of Patricia A. Bradford To Its Board Of Directors
NASDAQ RESUMED AT 01:05 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:00 PM
Phio Pharmaceuticals Corp reports results for the quarter ended in December - Earnings Summary
Brief: Phio Pharmaceuticals Reports 2021 Year End Results
Phio Pharmaceuticals Corp expected to post a loss of 32cents a share - Earnings Preview
Brief: Phio Pharmaceuticals Initiates In Vivo Studies Of Intasyl Based Antivirals Against Sars-Cov-2
U.S. STOCKS ON THE MOVE-Rivian, Tesla, Boeing, Aligos, Peloton
U.S. STOCKS ON THE MOVE-Vir Biotech, Phio Pharma, American Airlines
Phio Pharma gains on French regulatory nod for skin cancer drug trial
Brief: Phio Pharmaceuticals Announces Regulatory Clearance Of Clinical Trial For PH-762 To Treat Melanoma